# MOTILAL OSWAL

#### FINANCIAL SERVICES

# **Cello World**

| Estimate change |   | CMP: I |
|-----------------|---|--------|
| TP change       | Ļ | Muteo  |
| Rating change   |   |        |

| Bloomberg             | CELLO IN    |
|-----------------------|-------------|
| Equity Shares (m)     | 221         |
| M.Cap.(INRb)/(USDb)   | 135.6 / 1.6 |
| 52-Week Range (INR)   | 1025 / 596  |
| 1, 6, 12 Rel. Per (%) | -12/-26/-31 |
| 12M Avg Val (INR M)   | 212         |

#### Financials & Valuations (INR b)

|                      |       | ,     |       |
|----------------------|-------|-------|-------|
| Y/E Mar              | FY25E | FY26E | FY27E |
| Sales                | 21    | 24.6  | 29.3  |
| EBITDA               | 5     | 5.7   | 7.5   |
| Adj. PAT             | 3.4   | 3.7   | 5     |
| EBITDA Margin (%)    | 23.8  | 23.2  | 25.6  |
| Cons. Adj. EPS (INR) | 15.8  | 17.5  | 23.7  |
| EPS Gr. (%)          | 1.3   | 10.8  | 35.4  |
| BV/Sh. (INR)         | 69.2  | 86    | 108.9 |
| Ratios               |       |       |       |
| Net D:E              | -0.1  | -0.3  | -0.4  |
| RoE (%)              | 23    | 20    | 24    |
| RoCE (%)             | 24    | 24    | 26    |
| Valuations           |       |       |       |
| P/E (x)              | 39    | 35    | 26    |
| EV/EBITDA (x)        | 26    | 23    | 17    |

#### Shareholding Pattern (%)

| As on    | Dec-24 | Sep-24 | Dec-23 |
|----------|--------|--------|--------|
| Promoter | 75.0   | 75.0   | 78.1   |
| DII      | 13.5   | 13.6   | 12.8   |
| FII      | 7.5    | 7.7    | 3.0    |
| Others   | 4.0    | 3.7    | 6.2    |

Note: FII includes depository receipts

### MP: INR617 TP: INR800 (+30%)

Buy

# Muted Q3 performance; consumption-led rebound on the horizon

#### Earnings below estimates

- CELLO reported ~5% revenue growth in 3QFY25, driven by festive demand in the first half of the quarter. However, this was offset by a slowdown in consumption and discretionary spending later in the quarter.
- Growth in Consumerware (up 9% YoY) and Moulded Furniture & Allied products (up 7% YoY) was partially impacted by a decline in the Writing Instrument segment (down 11% YoY), despite export markets showing sequential recovery.
- Despite short-term headwinds, the company anticipates a rebound in consumption-driven demand due to the revised income tax policies in the new budget and untapped growth potential in quick commerce (currently ~1.5%-2.0% of e-commerce sales)
- Factoring in the weak 3Q performance, we cut our FY25/FY26/FY27 EPS estimates by 6%/19%/11% due to a delay in the ramp-up of Glassware, along with low revenue and margin for Writing Instrument caused by subdued export demand. We reiterate our Buy rating with a TP of INR800 (premised on 34x FY27E EPS)

#### Higher RM and discounting continue to hurt operating performance

- Consol. revenue grew ~5.7% /13.6% YoY/QoQ at INR5.6b (est. INR5.7b).
  EBITDA declined 3.6% YoY, while it grew 7% QoQ to INR1.3b (est. INR1.4b).
- EBITDA margins contracted 220bp YoY/130bp QoQ to 22.9% (est. 25.1%) as gross margins contracted 180bp YoY/190bp QoQ to 49.7%, led by discounting in the competitive market along with a rise in raw material costs.
- Adj. PAT grew 1.8%/6% YoY/QoQ to INR864m (est. INR939m).
- Consumerware segment's revenue (69% of total revenue in 3QFY25) grew 9% YoY/13% QoQ to INR3.9b.
- Writing Instrument segment's revenue (~14% revenue mix) declined 11% YoY, while revenue grew 11% QoQ to INR773m. On the other hand, the revenue of Moulded Furniture and Allied products (~17% revenue mix) grew 7% YoY/19% QoQ to INR931m.
- In 9MFY25, revenue/EBITDA/adj. PAT increased 4%/1%/3% to INR15.5b/ INR3.7b/INR2.5b.

#### Highlights from the management commentary

- Guidance: The company expects 12-14% revenue growth in FY26, with an upside to 15-17% if demand improves. EBITDA margins for FY26 are expected to remain stable, despite short-term pressures, primarily due to the ramp-up of Glassware (maximum impact likely to be ~100bp).
- Glassware Expansion: The newly commissioned glassware plant is currently at 50% capacity utilization and is expected to reach 75-80% in six months. It is expected to generate INR1.5b in FY26, scaling to INR2.5b in FY27 at peak capacity utilization.

Sumant Kumar - Research Analyst (Sumant.Kumar@MotilalOswal.com)

Research Analyst: Meet Jain (Meet.Jain@MotilalOswal.com) | Nirvik Saini Nirvik.Saini@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Demand Outlook: While exports remain challenging, early signs of recovery are visible. E-commerce and quick commerce are growing at 15-20%, driving revenue growth. New product launches contribute 15% of revenue, with further expansion in Writing Instruments and Premium Consumer Houseware. Additionally, higher e-commerce penetration and a capacity ramp-up in Glassware and Opalware are expected to support growth and margin recovery.


#### Valuation and view

- We expect the Writing Instrument segment to witness muted growth on a YoY basis in 4QFY25, followed by a recovery starting 1QFY26, led by a recovery in the export business. The Glassware facility began commercial production in Feb'25, and we anticipate a ramp-up in commercial production from 1QFY26 onwards.
- The inventory levels in consumer houseware have normalized, as festive demand helped clear excess stock. As a result, we expect healthy growth in the segment.
- Factoring in the weak 3Q performance, we cut our FY25/FY26/FY27 EPS estimates by 6%/19%/11% due to a delay in the ramp-up of Glassware and lowering revenue and margin for Writing Instrument caused by subdued export demand. We reiterate our Buy rating with a TP of INR800 (premised on 34x FY27E EPS).

| <b>Consolidated - Quarterly Ea</b> | rning M | odel           |       |       |                |       |       |       |        |        |       | (INR m)     |
|------------------------------------|---------|----------------|-------|-------|----------------|-------|-------|-------|--------|--------|-------|-------------|
| Y/E March                          |         | FY2            | 24    |       |                | FY2   | 5E    |       | FY24   | FY25E  | FY25E | Var         |
|                                    | 1Q      | 2Q             | 3Q    | 4Q    | 1Q             | 2Q    | 3Q    | 4QE   |        |        | 3Q    |             |
| Gross Sales                        | 4,718   | 4,890          | 5,271 | 5,125 | 5,007          | 4,901 | 5,568 | 5,555 | 20,003 | 21,031 | 5,695 | - <b>2%</b> |
| YoY Change (%)                     | NA      | NA             | NA    | 5.0   | 6.1            | 0.2   | 5.7   | 8.4   | 11.3   | 5.1    | 16.5  |             |
| Total Expenditure                  | 3,526   | 3 <i>,</i> 687 | 3,949 | 3,792 | 3,714          | 3,715 | 4,296 | 4,269 | 14,954 | 15,993 | 4,263 |             |
| EBITDA                             | 1,192   | 1,203          | 1,321 | 1,333 | 1,293          | 1,186 | 1,273 | 1,286 | 5,049  | 5,037  | 1,432 | -11%        |
| Margins (%)                        | 25.3    | 24.6           | 25.1  | 26.0  | 25.8           | 24.2  | 22.9  | 23.1  | 25.2   | 24.0   | 25.1  |             |
| Depreciation                       | 118     | 127            | 147   | 175   | 141            | 148   | 151   | 160   | 567    | 600    | 150   |             |
| Interest                           | 6       | 7              | 5     | 8     | 6              | 3     | 3     | 3     | 26     | 14     | 3     |             |
| Other Income                       | 81      | 107            | 45    | 66    | 60             | 133   | 124   | 125   | 299    | 442    | 65    |             |
| PBT before EO expense              | 1,149   | 1,176          | 1,214 | 1,215 | 1,206          | 1,168 | 1,243 | 1,248 | 4,755  | 4,865  | 1,344 |             |
| РВТ                                | 1,149   | 1,176          | 1,214 | 1,215 | 1 <b>,20</b> 6 | 1,168 | 1,243 | 1,248 | 4,755  | 4,865  | 1,344 |             |
| Тах                                | 321     | 310            | 307   | 250   | 311            | 300   | 318   | 313   | 1,188  | 1,242  | 339   |             |
| Rate (%)                           | 27.9    | 26.4           | 25.3  | 20.6  | 25.8           | 25.7  | 25.6  | 25.1  | 25.0   | 25.5   | 25.2  |             |
| MIt & Profit/Loss of Asso. Cos.    | 54      | 66             | 58    | 77    | 69             | 51    | 61    | 88    | 256    | 269    | 66    |             |
| Reported PAT                       | 774     | 800            | 849   | 888   | 826            | 816   | 864   | 847   | 3,311  | 3,353  | 939   |             |
| Adj PAT                            | 774     | 800            | 849   | 888   | 826            | 816   | 864   | 847   | 3,311  | 3,353  | 939   | -8%         |
| YoY Change (%)                     | NA      | NA             | NA    | -81.8 | 6.6            | 2.1   | 1.8   | -4.6  | 24.4   | 1.3    | 17.4  |             |
| Margins (%)                        | 16.4    | 16.4           | 16.1  | 17.3  | 16.5           | 16.7  | 15.5  | 15.2  | 16.6   | 15.9   | 16.5  |             |


# **Key Exhibits**






Source: Company, MOFSL

#### **Exhibit 3: Consolidated EBITDA trend**




Source: Company, MOFSL




Source: Company, MOFSL

#### Exhibit 4: Consolidated adj. PAT trend

Exhibit 2: Consolidated gross profit trend



Source: Company, MOFSL



Source: Company, MOFSL

Source: Company, MOFSL



## Highlights from the management commentary

#### Guidance

- The company expects revenue growth of 12-14% in FY26, with the possibility of reaching 15-17% if demand conditions improve.
- The newly added glassware plant is projected to contribute an additional 3.5-4% to overall revenue.
- The Consumerware segment is expected to grow steadily at 8%, while the Writing Instruments business is projected to achieve 8-10% growth.
- The Furniture segment, which has been showing signs of recovery, is anticipated to grow 5-7% in the coming year.

#### Margin trends & cost pressures

- EBITDA margins for FY26 are expected to remain stable, despite short-term pressures.
- The ramp-up of the glassware plant will temporarily impact margins by ~100bp.
- Gross margins have slightly contracted due to a 0.5-0.7% impact from higher discounting in a competitive market, coupled with rising raw material prices and unfavorable product mix, though better pricing strategies have helped offset these pressures.
- While EBIT margins will see a greater impact in the early phase of the glassware expansion, strong gross margins in the Glassware segment are expected to drive improvements in FY26.

### **Demand outlook**

- While the export market remains challenging, early signs of improvement are becoming visible.
- The company anticipates strong momentum in e-commerce and quick commerce channels, expecting 15-20% growth from these segments.
- Higher e-commerce penetration, along with capacity utilization ramp-up in the Glassware and Opalware segments, is expected to drive revenue growth and support margin recovery.
- New product launches already contribute 15% to total revenue, with further expansion planned in Writing Instrument and Premium Homeware. Additionally, the focus on premiumization and an improved product mix is expected to enhance margins and profitability.

#### Capacity expansion & capex plans

- The company has earmarked INR2.75b for capex in FY25, while FY26 capex is projected to be lower at INR750-1000m.
- The glassware plant, commissioned on 1<sup>st</sup> February and currently operating at 50% efficiency, is expected to scale up to 75-80% over the next six months. The first-year revenue contribution is estimated at INR1.5b, with expectations to increase to INR2.5b at full capacity in FY27.
- Opalware production utilization currently stands at 80% and is anticipated to improve further to 90-95% next year.
- The company is focused on expanding in quick commerce and premium product categories to strengthen its market share.

## MOTILAL OSWAL

#### Working capital & cash flow management

- Trade receivables improved from 124 days in Q2FY25 to 111 days, with a target to reduce by another 15 days.
- Inventory turnover has improved, with inventory days decreasing from 98 to 88, while trade payables remain stable at 25 days, ensuring a healthy cash flow cycle.
- The company continues to focus on working capital optimization, aiming for a 90-95 day cycle in the coming quarters.

#### Others

- Management is closely monitoring geopolitical risks that could affect export performance, while the domestic market remains strong, supported by favorable budget policies and interest rate cuts.
- Despite a competitive landscape, the company has not faced significant market share loss as industry-wide growth has been slower.
- Temporary margin contraction due to additional market discounts is expected to stabilize, while the company remains focused on improving ROCE and ROE to drive long-term shareholder value.

#### **Valuation and view**

- We expect the writing instrument segment to witness muted growth on a YoY basis in 4QFY25, followed by a recovery from 1QFY26 onwards, led by a recovery in the export business. The Glassware facility began commercial production in Feb'25 and we expect the ramp-up in commercial production from 1QFY26 onwards.
- The inventory levels in consumer houseware have normalized, as festive demand helped clear excess stocks. As a result, we expect healthy growth in the segment.
- Factoring in the weak 3Q performance, we cut our FY25/FY26/FY27 EPS estimates by 6%/19%/11% due to a delay in the ramp-up of Glassware and lowering revenue and margin for Writing Instrument caused by subdued export demand. We reiterate our Buy rating with a TP of INR800 (premised on 34x FY27E EPS)

| Earnings change |        | Old    |        |        | New    |        |       | Change |       |
|-----------------|--------|--------|--------|--------|--------|--------|-------|--------|-------|
| (INR m)         | FY25E  | FY26E  | FY27E  | FY25E  | FY26E  | FY27E  | FY25E | FY26E  | FY27E |
| Revenue         | 21,700 | 26,031 | 31,499 | 21,031 | 24,606 | 29,251 | -3%   | -5%    | -7%   |
| EBITDA          | 5,480  | 7,028  | 8,505  | 5,037  | 5,674  | 7,451  | -8%   | -19%   | -12%  |
| Adj. PAT        | 3,574  | 4,595  | 5,675  | 3,353  | 3,715  | 5,029  | -6%   | -19%   | -11%  |

#### 13 February 2025

# **Financials and valuations**

| Consolidated - Income Statement           |                  |            |              |                       |                     |                        | (INRm)                 |
|---|------------------|------------|--------------|-----------------------|---------------------|------------------------|------------------------|
| Y/E March                                 | FY21             | FY22       | FY23         | FY24                  | FY25E               | FY26E                  | FY27E                  |
| Total Income from Operations              | 10,495           | 13,592     | 17,967       | 20,003                | 21,031              | 24,606                 | 29,251                 |
| Change (%)                                | NA               | 29.5       | 32.2         | 11.3                  | 5.1                 | 17.00                  | 18.9                   |
| RM Cost                                   | 5,214            | 6,786      | 8,955        | 9,484                 | 10,177              | 11,516                 | 13,690                 |
| Employees Cost                            | 968              | 1,319      | 1,576        | 1,895                 | 2,135               | 2,411                  | 2,720                  |
| Other Expenses                            | 1,544            | 2,151      | 3,231        | 3,575                 | 3,682               | 5,005                  | 5,391                  |
| Total Expenditure                         | 7,727            | 10,256     | 13,762       | 14,954                | 15,993              | 18,933                 | 21,801                 |
| EBITDA                                    | 2,767            | 3,336      | 4,205        | 5,049                 | 5,037               | 5,674                  | 7,451                  |
| Margin (%)                                | 26.4             | 24.5       | 23.4         | 25.2                  | 24.0                | 23.1                   | 25.5                   |
| Depreciation                              | 489              | 476        | 503          | 567                   | 600                 | 797                    | 852                    |
| EBIT                                      | 2,278            | 2,860      | 3,702        | 4,481                 | 4,437               | 4,876                  | 6,599                  |
| Int. and Finance Charges                  | 23               | 29         | 18           | 26                    | 14                  | 2                      | 0                      |
| Other Income                              | 101              | 159        | 167          | 299                   | 442                 | 492                    | 585                    |
| PBT bef. EO Exp.                          | 2,357            | 2,991      | 3,852        | 4,755                 | 4,865               | 5,366                  | 7,184                  |
| EO Items                                  | 0                | 0          | 0            | 0                     | 0                   | 0                      | 0                      |
| PBT after EO Exp.                         | 2,357            | 2,991      | 3,852        | 4,755                 | 4,865               | 5,366                  | 7,184                  |
| Total Tax                                 | 701              | 796        | 1,001        | 1,189                 | 1,242               | 1,351                  | 1,808                  |
| Tax Rate (%)                              | 29.8             | 26.6       | 26.0         | 25.0                  | 25.5                | 25.2                   | 25.2                   |
| Minority Interest                         | 143              | 155        | 189          | 256                   | 269                 | 301                    | 347                    |
| Reported PAT                              | 1,512            | 2,040      | 2,661        | 3,310                 | 3,353               | 3,715                  | 5,029                  |
| Adjusted PAT                              | 1,512            | 2,040      | 2,661        | 3,310                 | 3,353               | 3,715                  | 5,029                  |
| Change (%)                                | NA               | 34.9       | 30.5         | 24.4                  | 1.3                 | 10.8                   | 35.4                   |
| Margin (%)                                | 14.4             | 15.0       | 14.8         | 16.5                  | 15.9                | 15.1                   | 17.2                   |
| Consolidated - Balance Sheet<br>Y/E March | FY21             | FY22       | FY23         | FY24                  | FY25E               | FY26E                  | (INRm)<br>FY27E        |
| Equity Share Capital                      | 0                | 0          | 975          | 1,061                 | 1,061               | 1,061                  | 1,061                  |
| Total Reserves                            | -1,068           | 876        | 2,390        | 10,431                | 13,625              | 17,180                 | 22,050                 |
| Net Worth                                 | -1,008<br>-1,068 | 876<br>876 | 3,365        | 10,431<br>11,492      | 13,025              |                        |                        |
| Minority Interest                         | 1,722            | 1,851      | 1,999        | 2,206                 | 2,475               | <b>18,242</b><br>2,777 | <b>23,112</b><br>3,123 |
| Total Loans                               | 3,221            | 4,525      | 3,261        | 3,627                 | 627                 | 2,777                  | 27                     |
| Deferred Tax Liabilities                  | 82               | 4,525      | 84           | 126                   | 126                 | 126                    | 126                    |
| Capital Employed                          | 3,957            | 7,336      | 8,709        | 17,452                | 17,915              | 21,172                 | 26,388                 |
| Gross Block                               | 2,901            | 2,898      |              |                       | 6,997               | 7,495                  | 7,995                  |
| Less: Accum. Deprn.                       | 309              | 312        | 3,388<br>671 | 4,857                 |                     | 2,636                  | 3,488                  |
| Net Fixed Assets                          | 2,592            | 2,586      | 2,717        | 1,238<br><b>3,619</b> | 1,838               | <b>4,860</b>           |                        |
| Capital WIP                               | 43               | 145        | 256          |                       | <b>5,159</b><br>310 | 312                    | <b>4,507</b><br>312    |
| Total Investments                         |                  |            |              | 1,800                 |                     |                        |                        |
| Current Investments                       | 1,197            | 1,500      | 1,769        | 1,698                 | 1,698               | 1,698                  | 1,698                  |
|   | 747              | 1,150      | 1,263        | 1,141                 | 1,141               | 1,141                  | 1,141                  |
| Curr. Assets, Loans&Adv.                  | 7,633            | 9,106      | 10,774       | 12,601                | 13,131              | 17,090                 | 23,184                 |
| Inventory                                 | 3,069            | 3,765      | 4,298        | 4,622                 | 4,782               | 5,595                  | 6,652                  |
| Account Receivables                       | 3,714            | 4,067      | 4,623        | 6,106                 | 5,474               | 6,404                  | 7,613                  |
| Cash and Bank Balance                     | 325              | 547        | 499          | 651                   | 1,589               | 3,586                  | 7,131                  |
| Loans and Advances                        | 525              | 726        | 1,354        | 1,223                 | 1,286               | 1,504                  | 1,788                  |
| Curr. Liability & Prov.                   | 7,508            | 6,000      | 6,808        | 2,266                 | 2,382               | 2,787                  | 3,314                  |
| Account Payables                          | 984              | 1,255      | 1,342        | 1,442                 | 1,516               | 1,774                  | 2,109                  |
| Other Current Liabilities                 | 6,471            | 4,685      | 5,428        | 783                   | 823                 | 963                    | 1,145                  |
| Provisions                                | 53               | 60         | 39           | 41                    | 43                  | 51                     | 60                     |
| Net Current Assets                        | 125              | 3,106      | 3,966        | 10,335                | 10,749              | 14,302                 | 19,871                 |
| Appl. of Funds                            | 3,957            | 7,336      | 8,709        | 17,452                | 17,915              | 21,172                 | 26,388                 |

# **Financials and valuations**

| Y/E March                          | FY21  | FY22  | FY23   | FY24   | FY25E  | FY26E   | FY27E    |
|------------------------------------|-------|-------|--------|--------|--------|---------|----------|
| Basic (INR)                        |       |       |        |        |        |         |          |
| EPS                                | 7.1   | 9.6   | 12.5   | 15.6   | 15.8   | 17.5    | 23.7     |
| Cash EPS                           | 9.4   | 11.9  | 14.9   | 18.3   | 18.6   | 21.3    | 27.7     |
| BV/Share                           | NA    | 4.1   | 15.9   | 54.1   | 69.2   | 86.0    | 108.9    |
| DPS                                | 0.0   | 0.0   | 0.0    | 0.8    | 0.8    | 0.8     | 0.8      |
| Payout (%)                         | 0.0   | 0.0   | 0.0    | 4.8    | 4.7    | 4.3     | 3.2      |
| Valuation (x)                      |       |       |        |        |        |         |          |
| P/E                                | 86.6  | 64.2  | 49.2   | 39.6   | 39.1   | 35.3    | 26.0     |
| Cash P/E                           | 65.4  | 52.1  | 41.4   | 33.8   | 33.1   | 29.0    | 22.3     |
| P/BV                               | NA    | 149.4 | 38.9   | 11.4   | 8.9    | 7.2     | 5.7      |
| EV/Sales                           | 11.8  | 10.0  | 6.9    | 6.7    | 6.2    | 5.2     | 4.3      |
| EV/EBITDA                          | 44.9  | 40.7  | 29.4   | 26.7   | 26.1   | 22.7    | 16.9     |
| Dividend Yield (%)                 | 0.0   | 0.0   | 0.0    | 0.1    | 0.1    | 0.1     | 0.1      |
| FCF per share                      | 8.7   | 6.4   | 6.4    | -1.6   | 17.3   | 10.7    | 14.7     |
| Return Ratios (%)                  |       |       |        |        |        |         |          |
| RoE                                | NA    | 232.8 | 79.1   | 28.8   | 22.8   | 20.4    | 24.3     |
| RoCE                               | NA    | 58.7  | 47.6   | 33.0   | 23.9   | 23.9    | 26.0     |
| RoIC                               | NA    | 55.7  | 48.4   | 34.5   | 23.9   | 24.4    | 30.1     |
| Working Capital Ratios             |       |       |        |        |        |         |          |
| Fixed Asset Turnover (x)           | 3.6   | 4.7   | 5.3    | 4.1    | 3.0    | 3.3     | 3.7      |
| Asset Turnover (x)                 | 2.7   | 1.9   | 2.1    | 1.1    | 1.2    | 1.2     | 1.1      |
| Inventory (Days)                   | 107   | 101   | 87     | 84     | 83     | 83      | 83       |
| Debtor (Days)                      | 129   | 109   | 94     | 111    | 95     | 95      | 95       |
| Creditor (Days)                    | 34    | 34    | 27     | 26     | 26     | 26      | 26       |
| Leverage Ratio (x)                 |       |       |        |        |        |         |          |
| Current Ratio                      | 1.0   | 1.5   | 1.6    | 5.6    | 5.5    | 6.1     | 7.0      |
| Interest Cover Ratio               | 100.1 | 100.4 | 210.8  | 175.5  | 314.4  | 2,291.3 | 37,015.5 |
| Net Debt/Equity                    | NA    | 3.2   | 0.4    | 0.2    | -0.1   | -0.3    | -0.4     |
|                                    |       |       |        |        |        |         |          |
| Consolidated - Cash Flow Statement |       |       |        |        |        |         | (INRm)   |
| Y/E March                          | FY21  | FY22  | FY23   | FY24   | FY25E  | FY26E   | FY27E    |
| OP/(Loss) before Tax               | 2,357 | 2,991 | 3,852  | 4,750  | 4,865  | 5,366   | 7,184    |
| Depreciation                       | 489   | 476   | 503    | 567    | 600    | 797     | 852      |
| Interest & Finance Charges         | 22    | 26    | 14     | 26     | -428   | -490    | -585     |
| Direct Taxes Paid                  | -681  | -843  | -1,010 | -1,160 | -1,242 | -1,351  | -1,808   |
| (Inc)/Dec in WC                    | -221  | -728  | -1,150 | -1,667 | 525    | -1,557  | -2,023   |
| CF from Operations                 | 1,966 | 1,923 | 2,210  | 2,516  | 4,320  | 2,766   | 3,620    |
|                                    |       | -     | -      |        |        | -       |          |

|                           |        |        | _,     | _/     | _/_ · - | _,     | _,     |
|---------------------------|--------|--------|--------|--------|---------|--------|--------|
| (Inc)/Dec in WC           | -221   | -728   | -1,150 | -1,667 | 525     | -1,557 | -2,023 |
| CF from Operations        | 1,966  | 1,923  | 2,210  | 2,516  | 4,320   | 2,766  | 3,620  |
| Others                    | -29    | -50    | 64     | -204   | 0       | 0      | 0      |
| CF from Operating incl EO | 1,936  | 1,873  | 2,274  | 2,312  | 4,320   | 2,766  | 3,620  |
| (Inc)/Dec in FA           | -248   | -516   | -1,032 | -2,649 | -650    | -500   | -500   |
| Free Cash Flow            | 1,688  | 1,356  | 1,242  | -337   | 3,670   | 2,266  | 3,120  |
| (Pur)/Sale of Investments | 0      | 0      | 0      | 0      | 0       | 0      | 0      |
| Others                    | -126   | -2,075 | -4,527 | 228    | 442     | 492    | 585    |
| CF from Investments       | -375   | -2,592 | -5,559 | -2,421 | -208    | -8     | 85     |
| Issue of Shares           | 0      | 0      | -151   | 0      | 0       | 0      | 0      |
| Inc/(Dec) in Debt         | 1,775  | 1,254  | -1,264 | 191    | -3,000  | -600   | 0      |
| Interest Paid             | -15    | -16    | -5     | -22    | -14     | -2     | 0      |
| Dividend Paid             | -1     | -60    | -96    | -46    | -159    | -159   | -159   |
| Others                    | -3,086 | -237   | 4,754  | 138    | 0       | 0      | 0      |
| CF from Fin. Activity     | -1,328 | 941    | 3,238  | 260    | -3,173  | -761   | -159   |
| Inc/Dec of Cash           | 233    | 222    | -47    | 151    | 939     | 1,996  | 3,545  |
| Opening Balance           | 91     | 325    | 547    | 499    | 651     | 1,589  | 3,586  |
| Closing Balance           | 325    | 547    | 499    | 651    | 1,589   | 3,586  | 7,131  |

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

ΝΟΤΕS

#### Explanation of Investment Rating

| Expected return (over 12-month)  |  |  |  |  |  |
|--|--|--|--|--|--|
| >=15%  |  |  |  |  |  |
| < - 10%  |  |  |  |  |  |
| < - 10 % to 15%  |  |  |  |  |  |
| Rating may undergo a change  |  |  |  |  |  |
| NOT RATED We have forward looking estimates for the stock but we refrain from assigning recommendation |  |  |  |  |  |
|  |  |  |  |  |  |

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on <u>www.motilaloswal.com</u>. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Scock Exchange of Availation of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at http://onlinereports.motilaloswal.com/Dormant/documents/List%200f%20Associate%20companies.pdf

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <a href="https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx">https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx</a>

A graph of daily closing prices of securities is available at <u>www.nseindia.com</u>, <u>www.bseindia.com</u>. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH00000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong. For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors. Any employee on registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and under applicable empaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S. MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL . In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to <u>grievances@motilaloswal.com</u>.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

#### Specific Disclosures

 Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes. Nature of Financial interest is holding equity shares or derivatives of the subject company

2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.

MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report:No

- 3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- 4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- 5. Research Analyst has not served as an officer, director or employee of subject company(ies).
- 6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- 7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.

- 8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- 9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- 10. MOFSL has not engaged in market making activity for the subject company.

#### The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report. **Disclaimer:** 

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263;

www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

| Grie | vance | Redress |
|------|-------|---------|
|      |       |         |

| Contact Person     | Contact No.                 | Email ID                     |
|--------------------|-----------------------------|------------------------------|
| Ms. Hemangi Date   | 022 40548000 / 022 67490600 | query@motilaloswal.com       |
| Ms. Kumud Upadhyay | 022 40548082                | servicehead@motilaloswal.com |
| Mr. Ajay Menon     | 022 40548083                | am@motilaloswal.com          |

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.